文献速递慢性肾脏病肾小球疾病

载脂蛋白L1相关肾病中的替代终点:三个队列的评估

Surrogate End Points in Apolipoprotein L1 - Associated Kidney Disease : Evaluation in Three Cohorts.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-11-05

结果显示,APOL1高危基因型者3年GFR相关替代终点及长期肾衰竭风险更高,但替代终点与临床结局的关联在不同基因型间无一致差异,支持在APOL1肾病中使用替代终点。

要点

  • APOL1高危基因型者3年GFR相关替代终点和长期肾衰竭风险更高。
  • 替代终点与肾衰竭强关联,与心衰、心血管病和死亡关联较弱但显著。
  • 不同APOL1基因型间替代终点与临床结局的关联无一致差异。

核心结论

  • APOL1高危基因型个体比低危基因型个体更易发生3年GFR相关终点和长期肾衰竭。
  • 短期临床结局关联在不同APOL1基因型间无一致差异,支持在APOL1相关肾病中使用替代终点。

研究设计与样本

  • 随机效应荟萃分析,纳入ARIC研究(N=3071)、CRIC研究(N=998)和AASK研究(N=609)的黑人参与者。

主要发现

  • AASK中22%、CRIC中18%、ARIC中13%的参与者为APOL1高危基因型。
  • APOL1高危基因型者所有3年GFR结局风险更高,但尿蛋白肌酐比值加倍风险无差异。
  • 3年结局与肾衰竭强关联,与心衰、心血管病和死亡关联较弱但统计学显著。

关键数值与推荐

  • 替代终点包括3年GFR下降30%和40%、尿蛋白肌酐比值加倍、GFR年下降>3 ml/min per 1.73 m2。
  • 临床结局包括需要肾脏替代治疗的肾衰竭、心衰、心血管病和3年后死亡。

临床怎么用

  • 在APOL1相关肾病临床试验中,可考虑使用3年GFR相关替代终点预测长期肾衰竭风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Apolipoprotein L1 (APOL1) high-risk genotype had higher risk of 3-year GFR-related surrogate end points and long-term kidney failure than those with the low-risk genotype. No consistent difference in surrogate–clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 kidney disease. BACKGROUND: Surrogate end points for the clinical outcome of kidney failure have been accepted by the US Food and Drug Administration. However, they have not been specifically evaluated in Apolipoprotein L1 (APOL1)-associated kidney disease. METHODS: This random-effects meta-analysis included Black participants in the Atherosclerosis Risk in Communities study (N=3071), Chronic Renal Insufficiency Cohort (N=998), and African American Study of Kidney Disease and Hypertension (N=609). Surrogate end points included a 3-year 30% and 40% decline in GFR, doubling of urine protein–creatinine ratio, and >3 ml/min per 1.73 m2 per year decline in GFR. Clinical outcomes included kidney failure requiring KRT, heart failure, cardiovascular disease, and death after 3 years. RESULTS: 22% in the African American Study of Kidney Disease and Hypertension, 18% in the Chronic Renal Insufficiency Cohort, and 13% in the Atherosclerosis Risk in Communities study had the APOL1 high-risk genotype. Participants with the APOL1 high-risk genotype had higher risk of all 3-year GFR outcomes but not doubling of urine protein–creatinine ratio, as well as kidney failure after 3 years. The 3-year outcomes were strongly associated with kidney failure with weaker but statistically significant associations with the development of heart failure, cardiovascular disease, and mortality. There were no differences in associations between short-term and long-term clinical outcomes by APOL1 risk status. CONCLUSIONS: Individuals with the APOL1 high-risk genotype were more susceptible to 3-year GFR-related end points and long-term kidney failure than individuals with the APOL1 low-risk genotype. There was no consistent difference in short-term clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1-associated kidney disease.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Rosenberg AT, Flaherty C, Anderson AH, et al. Surrogate End Points in Apolipoprotein L1 - Associated Kidney Disease : Evaluation in Three Cohorts. Clin J Am Soc Nephrol. 2024. PMID: 39499577. doi:10.2215/CJN.0000000000000575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。